Model: MDA-MB-231   End Point Biomarker Treatmenta Concentration 2-OHE1: 16α-OHE1b AI Coloniesc DMSO 0.1% 0.4 ±0.1d 23.8 ±2.2f I3C 50 µM 2.4 ±0.3e 9.0 ±1.2g

Table 4: Modulation of End Point Biomarkers in Model for Triple Negative Breast Cancer. aI3C at its maximum cytostatic concentration. bConcentration of individual E2 metabolites determined by the tritium exchange assay after a 48 hr treatment. Mean±SD, N=3 per treatment group. Data analyzed by the 2-sample t test comparing the data from the DMSO group (Control). cAnchorage independent (AI) colony counts at day 21 post-seeding of 1,000 cell per well of six well plates. Mean±SD, N=18 per treatment group. Data analyzed by the 2-sample t test comparing the data from the DMSO group (Control). d-eP= 0.001. f-gP=0.01.